Mercator MedSystems has obtained $6.5 million in a Series B financing round, which it will use in part to begin sales of its Cricket and Bullfrog microinfusion devices in the U.S., Europe and Australia. The devices, which already have FDA clearance and CE mark approval in Europe, are used to safely deliver drugs to deep tissue through blood vessel walls.
Mercator gets $6.5M boost to market microinfusion devices
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.